ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "dermatomyositis"

  • Abstract Number: 2069 • ACR Convergence 2024

    Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort

    Lovely Kumari1, VISHNU KONERU2, subin Philip1, sai Kumar Dunga3, Mamatha gorijavulu4, Aishwarya Gopal5, Christina Mariaselvam6, Molly Thabah7, Vir Singh Negi8 and Chengappa Kavadichanda9, 1JIPMER,PUDUCHERRY, PUDUCHERRY, Puducherry, India, 2JIPMER,PUDUCHERRY, PUDUCHERRY, India, 3JIPMER,PUDUCHERRY, VIZAG, Andhra Pradesh, India, 4JIPMER,PUDUCHERRY, HYDERABAD, Andhra Pradesh, India, 5Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, 6JIPMER, Puducherry, Puducherry, India, 7Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, 8AIIMS BILASPUR, BILASPUR, Himachal Pradesh, India, 9Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India

    Background/Purpose: Idiopathic inflammatory myopathy (IIM) carries an elevated cancer risk. The International Myositis Assessment and Clinical Studies Group (IMACS) has issued evidence-based guidelines for cancer…
  • Abstract Number: 0339 • ACR Convergence 2024

    Clinical Characteristics Associated with Inpatient Mortality in Dermatomyositis Patients: A Single Center Retrospective Cohort Study

    Anjana Srikumar, Keon Niknejad, Maria Kaltchenko and Jun Kang, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease associated with higher rates of hospitalization, longer lengths of stay, higher mean hospitalization costs, and increased inpatient…
  • Abstract Number: 1152 • ACR Convergence 2024

    Nailfold Videocapillaroscopy Abnormalities in Different Autoimmune Inflammatory Myopathy Subsets

    Thaisa Cotton1, Valérie Leclair2, Claudie Berger3, Yves Troyanov4, marie Hudson2 and Geneviève Gyger2, and Canadian Inflammatory Myopathy Study (CIMS), 1Université de Montréal, Montreal, QC, Canada, 2McGill University, Montreal, QC, Canada, 3Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada

    Background/Purpose: Nailfold videocapillaroscopy (NVC) alterations have mostly been described in autoimmune inflammatory myopathies (AIM) classified using Bohan and Peter criteria. The aim of this study…
  • Abstract Number: 1284 • ACR Convergence 2024

    Unlocking Insights into Juvenile Dermatomyositis: Clinical and Demographic Profiles Paired with Total Improvement Scores at a Tertiary Center

    keerthivardhan yerram1, phanikumar devarasetti1 and Liza Rajasekhar2, 1Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, 2Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disorder that predominantly affects the skin and muscles in children under the age of sixteen. Literature on…
  • Abstract Number: 2081 • ACR Convergence 2024

    Proteomic Profiling of Urine Reveals Biomarker Candidates for Idiopathic Inflammatory Myopathies

    Xueting Yuan1, Zhengguang Guo2, Jia Shi1, Shuang Zhou3, Chanyuan Wu4, Jiuliang Zhao3, Dong Xu5, Mengtao Li6, Wei Sun2, qian wang6 and Xiaofeng Zeng7, 1Peking Union Medical College, Beijing, China, 2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China, 3Peking union medical college hospital, Beijing, China, 4Peking Union Medical College Hospital, Chinese Academy of Medical Sciences& Peking Union Medical College, Beijing, China, 5Peking Union Medical College Hospital, Dong Cheng District, Beijing, China, 6Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, 7Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare heterogeneous group of autoimmune diseases characterized by immune-mediated muscle injury. We aimed to examine urine proteomic signatures…
  • Abstract Number: 0341 • ACR Convergence 2024

    Efficacy and Safety of Nintedanib in Patients with Idiopathic Inflammatory Myopathy-related Interstitial Lung Disease

    Kaito Aoki1, Keigo Shimura1, Toshiki Ohisa1, Akira Ishii1, Mai Sugiyama2, Yuichiro Ota1, Ayumi Nishikawa3, Noriko Sasaki3, Chiho Yamada1 and Shinji Sato2, 1Tokai University School of Medicine, Isehara, Japan, 2Tokai University, Isehara, Japan, 3Tokai University Hachioji Hospital, Hachioji, Japan

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic inflammatory disorders that affect muscle, skin and lung to varying degrees. Interstitial lung disease (ILD) is a major…
  • Abstract Number: 1154 • ACR Convergence 2024

    Comparative Transcriptome Analysis of Murine Model and Human Samples in Anti-Melanoma Differentiation Associated Gene 5 Antibody-positive Rapidly Progressive Interstitial Lung Disease

    Yuki Ichimura1, Risa Konishi2, Tadatsune Iida3, Kousuke Negishi4 and Naoko Okiyama5, 1Tokyo Women’s Medical University, Tokyo, Japan, 2University of Tsukuba, Tokyo, Japan, 3Institute of Science Tokyo, Tokyo, Japan, 4Kawakita General Hospital, Tokyo, Japan, 5Institute of Science Tokyo, Toky, Japan

    Background/Purpose: Anti-Melanoma differentiation associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) frequently presents with rapidly progressive interstitial lung disease (RP-ILD), leading to a high mortality rate…
  • Abstract Number: 1424 • ACR Convergence 2024

    Associations of Human Leukocyte Antigens (HLA) Class II with Interstitial Lung Disease (ILD) in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs). A Prospective Study in Sequential Patients with SARD-ILD

    Panagiotis Panagopoulos1, Loukas chatzis2, Vasiliki Kitsiou3, Katerina Tarassi3, Eirini Chatzinikita4, Katerina Malagari5, Theodoros Vassilakopoulos4, Alexandra Tsirogianni3, Andreas Goules6 and Athanasios Tzioufas7, 1Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 2Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, 3Immunology and Histocompatibility Department, Evangelismos General Hospital, Athens, Greece, 4Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 52nd Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 6GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, 7LAIKO HOSPITAL, Athens, Greece

    Background/Purpose: Genetic studies in various systemic autoimmune rheumatic diseases (SARDs) support that human leukocyte antigen (HLA) class II alleles are associated with specific autoimmune disorders…
  • Abstract Number: 2183 • ACR Convergence 2024

    Accuracy of AI Tools for Diagnosis of Connective Tissue Disease

    Indira Sriram1, Gabriel Tarshish2 and Megan Curran2, 1University of Colorado, Aurora, CO, 2Children's Hospital Colorado, Aurora, CO

    Background/Purpose: In this work, we study the ability of generative artificial intelligence (AI) based tools to diagnose pediatric rheumatological diseases. Specifically, we seek to answer…
  • Abstract Number: 0345 • ACR Convergence 2024

    Treatment Patterns and Glucocorticoid Burden of Dermatomyositis Patients: A Cohort Study in the University of Pittsburgh’s Myositis Registry

    Chester Oddis1, Jan Feifel2, Dana Ascherman3, Diane Carol Koontz4, Caroline Foch2, Luisa Henkel5, Jeffrey M. Muir6, Deborah Denis7 and Rohit Aggarwal8, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 2the healthcare business of Merck KGaA, Darmstadt, Germany, 3Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 4University of Pittsburgh, Pittsburgh, PA, 5Merck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany, Weiterstadt, Germany, 6Cytel, Inc., Toronto, Canada, 7EMD Serono, Rockland, MA, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: Glucocorticoids (GC) in high doses remain the first-line treatment for dermatomyositis (DM). One or more immunosuppressive agents are given concomitantly as steroid-sparing agents to…
  • Abstract Number: 1155 • ACR Convergence 2024

    Stratification of Cancer Risk in Idiopathic Inflammatory Myopathies. Application of the IMACS Guidelines to Enhance Screening

    Miriam Retuerto Guerrero1, Clara Moriano2, cristiana sieiro santos3 and elvira Diez álvarez4, 1Complejo Asistencial Universitario de León, Leon, Spain, 2Hospital León, LEON, Spain, 3Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, 4Complejo Asistencial Universitario de Leon, Leon

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) carry an elevated risk of cancer incidence. Recently published International Guidelines for IIM-associated cancer screening from the Myositis Assessment and…
  • Abstract Number: 1537 • ACR Convergence 2024

    Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases

    Kelly A. Pike1, Nadine Fradet1, Samuel Gaudreault1, Alexander M Skeldon2, Ramsay E. Beveridge2, Patrick Cyr2, Nicolas Sgarioto2, Philippe Le Gros3, Eleftheria Seliniotakis2, Valerie Dumais2, Jacklyn Smith2, James I.P Stewart2, Mehrnaz Gharaee-Kermani4, Michelle J Kahlenberg4 and Michael A. Crackower2, 1Ventus Therapeutics, Saint-Laurent, QC, Canada, 2Ventus Therapeutics, Saint-Laurent, Canada, 3Ventus Therapeutics, Montreal, QC, Canada, 4University of Michigan, Ann Arbor, MI

    Background/Purpose: Cyclic GMP-AMP synthase (cGAS) is a nucleic acid sensor that plays a central role in anti-viral responses. Following the detection of intracellular double-stranded DNA,…
  • Abstract Number: 2404 • ACR Convergence 2024

    Nailfold Dermoscopy: A Valuable Tool for Differentiating Dermatomyositis from Systemic Lupus Erythematosus

    Caroline Stone1, Daniella Faden1, Lillian Xie1, Lais Lopes Almeida Gomes1, Joshua Dan1, Cristina Ricco1, Ahmed Eldaboush1 and Victoria Werth2, 1University of Pennsylvania, philadelphia, PA, 2University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Dermatoscopes are emerging as efficient, valuable alternatives to capillaroscopy for evaluating rheumatologic conditions. Second to systemic sclerosis, nailfold capillaroscopy abnormalities are most consistently reported…
  • Abstract Number: 0347 • ACR Convergence 2024

    Dermato-polymyositis Mortality in U.S. Population: Declining Cancer and Cardiovascular Diseases Among the Leading Underlying Causes of Death over Two Decades

    Elizabeth Matz1 and Ram Singh2, 1UCLA David Geffen School of Medicine, Los Angeles, 2UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Dermatomyositis and polymyositis (DM/PM) are chronic inflammatory muscle diseases that may cause premature death due to progressive muscle weakness, lung disease, and disease and…
  • Abstract Number: 1158 • ACR Convergence 2024

    Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients

    Sehreen Mumtaz1, Megan Sullivan2, Maximiliano Diaz Menindez3, Emily Craver4 and Florentina Berianu5, 1Mayo Clinic, Florida, Jacksonville, FL, 2Mayo Clinic Arizona, Scottsdale, AZ, 3Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, 4Mayo Clinic Florida, Jacksonville, FL, 5mayo clinic, Ponte Vedra Beach, FL

    Background/Purpose: Nailfold videocapillaroscopy (NVC) findings have been studied to differ in different subsets of myositis-specific autoantibodies (MSAs) associated inflammatory myopathies. Prior investigations observed a statistically…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology